GlassScriptPhysician profile
Soumya Nadella
NPI 1316350028
$8,122.92
in general payments reported to CMS, 2019-2025
44 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $425 · 2021: $734 · 2022: $1,118 · 2023: $1,559 · 2024: $1,918 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,616.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $922.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $821.97 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $609.11 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $526.51 | 2021-2025 | Minimed 780g, Interstim, Arctic Front Advance |
| Sanofi-Aventis U.S. LLC | $445.19 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $426.95 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $409.17 | 2020-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $390.37 | 2022-2025 | |
| Amgen INC. | $369.62 | 2020-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.27 | 2021-2025 | Jardiance, Tradjenta |
| Xeris Pharmaceuticals, INC. | $272.30 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $256.58 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $202.02 | 2021-2025 | Strensiq |
| Mannkind Corporation | $196.19 | 2019-2025 | Afrezza |
| Recordati_rare_diseases_inc. | $173.67 | 2023-2025 | Isturisa, Signifor Lar |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $158.33 | 2025 | Twiist |
| Insulet Corporation | $150.86 | 2021-2025 | Omnipod |
| Ibsa Pharma INC. | $132.40 | 2022-2025 | Tirosint, Tirosint, Licart |
| Esperion Therapeutics, INC. | $122.35 | 2020-2025 | Nexletol |
| Corcept Therapeutics | $113.16 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $110.74 | 2019-2022 | |
| Amarin Pharma, INC. | $110.04 | 2020-2022 | |
| Medicure Pharma INC. | $104.73 | 2023 | Zypitamag |
| Beta Bionics, INC. | $104.52 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $74.96 | 2020-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $69.99 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $61.97 | 2025 | Yorvipath |
| Nevro Corp. | $54.73 | 2022-2023 | Senza |
| Horizon Therapeutics Plc | $50.78 | 2022-2023 | Tepezza |
| Radius Health, INC. | $50.05 | 2021-2025 | Tymlos |
| Antares Pharma, INC. | $41.54 | 2025 | Xyosted |
| Ultragenyx Pharmaceutical INC. | $40.30 | 2021-2023 | |
| Amryt Pharma Holdings LTD | $37.27 | 2020-2021 | |
| Almatica Pharma LLC | $35.11 | 2025 | Teriparatide |
| Medtronic Minimed, INC. | $31.12 | 2020 | |
| Neurocrine Biosciences, INC. | $21.27 | 2024 | |
| Cequr Corporation | $19.51 | 2025 | Cequr Simplicity |
| Daiichi Sankyo INC. | $19.47 | 2023 | Injectafer |
| Allergan, INC. | $19.20 | 2020 | |
| Kyowa Kirin, INC. | $18.53 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $17.26 | 2021 | |
| Rgh Enterprises LLC | $16.11 | 2025 | |
| Ascensia Diabetes Care US INC. | $15.40 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soumya Nadella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.